|
PNPLA8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.86399784496416E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.96390015361203E-10 |
| Normal-vs-Stage2 |
4.18329999973821E-07 |
| Normal-vs-Stage3 |
2.14595008429797E-12 |
| Normal-vs-Stage4 |
3.69704267200177E-14 |
| Stage1-vs-Stage2 |
3.626800E-01 |
| Stage1-vs-Stage3 |
8.418000E-03 |
| Stage1-vs-Stage4 |
1.039880E-03 |
| Stage2-vs-Stage3 |
1.026430E-02 |
| Stage2-vs-Stage4 |
9.181300E-04 |
| Stage3-vs-Stage4 |
2.396400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.48214815157644E-12 |
| Normal-vs-AfricanAmerican |
2.10049999999073E-05 |
| Normal-vs-Asian |
1.72049999802582E-08 |
| Caucasian-vs-AfricanAmerican |
5.217600E-01 |
| Caucasian-vs-Asian |
6.944400E-01 |
| AfricanAmerican-vs-Asian |
8.034200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.93145540964224E-12 |
| Normal-vs-Female |
4.28690416498512E-11 |
| Male-vs-Female |
2.010800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.45630207682279E-12 |
| Normal-vs-Age(41-60Yrs) |
4.50750547997814E-12 |
| Normal-vs-Age(61-80Yrs) |
5.43398659402783E-12 |
| Normal-vs-Age(81-100Yrs) |
2.676800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.010500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.068000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.902200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.525400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.440400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.109200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.118700E-03 |
| Classical-VS-Follicular |
2.643600E-01 |
| Classical-VS-Other |
2.331400E-01 |
| Classical-VS-Normal |
1.84389947754937E-10 |
| Tall-VS-Follicular |
1.759540E-03 |
| Tall-VS-Other |
9.313000E-01 |
| Tall-VS-Normal |
7.86704035249386E-13 |
| Follicular-VS-Other |
1.587450E-01 |
| Follicular-VS-Normal |
2.86110002356565E-09 |
| Other-VS-Normal |
3.383000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.08090211728518E-11 |
| Normal-vs-N1 |
5.81390491305456E-12 |
| N0-vs-N1 |
1.130430E-01 |
|
|
